In the last few years, the rapid technological development of biomedical
research has created the need for high-tech services and products
which are provided by dedicated and specialized biotech companies.
In this respect, Primm is a leading biotech company which exploits
modern technologies both for high value R&D projects and for
providing specialized services for academic, governmental and industrial
s.r.l. was founded in 1990, initially as a provider of synthetic
oligonucleotides, and since has expanded its services to the areas
of peptide synthesis, polyclonal and monoclonal antibodies, kits
for DNA purification, DNA and protein sequencing, mass spectrometry
and the development of recombinant proteins and immunometric assays.
Today, Primm is the leading Italian company in these areas, and
several qualified industrial and academic laboratories in Europe
and United States have chosen Primm as their partner for selected
biotechnological services. Since 1996, Primm has also invested in
proprietary R&D projects based on its core technologies. At
present, Primm has laboratories, manufacturing facilities and commercial
offices in Italy and USA.
Its main facility is located at the San Raffaele Biomedical Science
Park, Milan, providing several core services to the local scientific
community and where scientific interactions are developed on a routine
In 1998, the company expanded its activities through the acquisition
of a top-class animal facility and laboratories located in the area
of Treviso (Italy). This site is used for the production of polyclonal
and monoclonal antibodies and to develop and perform various services,
such as animal breeding and mainteinance, and pre-clinical studies.
Primm has grown not only as a service company, having a strong experience
in industrial R&D, but it has also invested its own resources
in selected projects with potential industrial outcome.
Through Primm's efforts, specific projects are brought to an appropriate
level of maturation where joint ventures with larger industrial
partners can be established. In the past few years, several research
projects have been carried out in close collaboration with important
Italian and international companies and academic institution. In
particular, the main focus has been the design, synthesis and pharmaceutical
development of novel bioactive peptides for various therapeutical
applications. Some of these projects have led to the filing and
acquisition of relevant patents and now are in pre-clinical phases.
Another relevant area of R&D activities is related to the development
of recombinant strains and technologies for the industrial production
of pharmaceuticals, which is also performed in collaboration with
a important industrial partners.
DNA and RNA synthesis
Oligonucelotides are synthesized at various scales of synthesis,
purified, labelled and modified according to individual request.
Additional services include custom labelling and modifications of
Automated DNA sequencing services provide an excellent way to obtain
high quality sequences that are accepted for publication by journals
and databanks alike. Primm offers full sequencing projects, single
run sequencing and mutation analysis to cover all the researcher's
Single run sequencing provides the researcher with the possibility
to submit DNA for one primer reactions using universal or specific
priers in a single run sequence which usually provides350-400 basepairs
of readable sequence. Sequence based mutation detection is being
used more frequently to screen for genetic mutations in disease.
Characterizing genetic mutations by sequencing is best performed
with a strategy based on the use of dye primer sequencing of PCR
products. In full sequencing projects, Primm designs and synthesizes
all primers necessary to sequence both strands utilizing the walking
Primm is present in the international market as a producer of synthetic
peptides. Synthetic peptides have assumed an important role in modern
research activities of biochemistry, cell biology, immunology and
Indeed, the possibility, for example, to use immunopeptides as antigens
in the production of specific antibodies for ELISA techniques or
as immunological probes in gene-screening or gene expression experiments
represents an extraordinary opportunity. Similarly, the use of bioactive
peptides in studies of biological activity associated with specific
epitopes of larger polypeptides (proteins and/or enzymes) allows
the investigation of either the biochemical/structural parameters
or the characterization of specific receptors or ligands. Aware
of the enormous interest covered by synthetic peptides, Primm is
presently offering the services on very competitive terms, both
in the quality and economical aspects. The quality of the peptides
produced by Primm is routinely verified by MALDI-TOF Mass Spectrometry
analysis which is considered to be one of the most reliable analytical
tools in structural investigations.
and monoclonal antibodies
Primm provides an efficient production service of polyclonal antibodies
from rabbits immunized treated with synthetic peptides or antigens
supplied by the customer. Primm also offers a monoclonal antibody
production service, as well as the production of ascitic fluid from
hybridomas, bulk quantity productions of purified monoclonal antibodies,
characterizations of the biochemical and immunological characteristics
of antibodies, including the kinetic parameters of antigen-antibody
interactions by plasmon resonance.
and protein analysis
The structural analysis of peptides and proteins constitutes one
of the most relevant topics in biotechnology, due to its importance
in basic science and in the quality control of synthetic peptides
and/or recombinant proteins.
Primm offers a wide range of technologically advanced services which
are very important for the structural characterization and development
of bio-molecules, such as peptides and proteins. These services
are based on the integration of classical biochemical techniques
with advanced mass spectrometry procedures, providing the following
- N-terminal protein sequencing;
- Determination of the accurate molecular weight of a peptide or
- Analysis of synthetic peptides;
- Characterization of genetic variants and mutants;
- Identification of post-translational modifications;
- Identification of labelled residues;
- Defintion of the oligosaccharide structure of glycoproteins;
- Amino acid sugar and lipid analysis.
Primm is engaged in several industrial collaborations related to
the development and exploitations of expression systems and production
processes based on recombinant DNA technologies. Some of the activities
include the cloning of new genes or already published ones (from
cDNA or genomic), DNA sequencing to verify the cloned sequence,
and development or recombinant strains (E. coli, yeast or mammalian
cells) expressing heterologous proteins.
Protocols for fermentation, downstream processing, purification
and characterization of the biological activity of the recombinant
protein are also provided.